ITOS / ITeos Therapeutics, Inc. (ITOS) Reports Q1 Loss, Misses Revenue Estimates

iTeos Therapeutics, Inc. (ITOS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate re more_horizontal

iTeos Therapeutics focuses on developing immuno-oncology treatments for cancer patients, with a focus on TIGIT-targeted therapies. Roche's accidental more_horizontal

Today, we circle back on small oncology concern iTeos Therapeutics, Inc. for the first time since last July. The company is advancing its two primary more_horizontal

ITeos Therapeutics, Inc. (ITOS) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compare more_horizontal

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 35.71% and 30.97%, respectively, for the quarter ended December 2022. Do t more_horizontal

iTeos Therapeutics, Inc. has a major deal with GSK, but a rival drug failed, bringing iTeos Therapeutics down. This happened once before with another more_horizontal

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of -57.14% and 53.65%, respectively, for the quarter ended September 2022. Do more_horizontal

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 278.29% and 181.44%, respectively, for the quarter ended December 2021. Do more_horizontal